| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/12/2006 | US7105482 Administering {(3R, 4S, 5S, 6R)-5-Methoxy-4-[(2R, 3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino}-3-methyl-butyric acid methyl ester; parasitic infections, thymoma, and lymphoid malignancies; prevents the metabolic degradation of the angiogenesis inhibitor |
| 09/12/2006 | US7105481 Method for stimulating connective tissue growth or wound healing |
| 09/12/2006 | US7105480 Administering a leptin or derivative, homologue, analogue, chemical equivalent or agonist to inhibit, reduce or delay onset or progression of bone resorption; treatiing osteoporosis and Paget's disease |
| 09/12/2006 | US7105342 In vitro proliferation of pluripotent neural stem cell; obtain mammalian neural tissues, dissociate neural tissue into suspension, culture, passaging neural stem cell progeny to a second culture and propagate cells |
| 09/12/2006 | US7105334 Cleaving chondroitin sulfate with a modified chondroitinase B having the amino acid sequence of the mature peptide; modifying with individual residues involved in substrate binding and catalysis |
| 09/12/2006 | US7105332 Isolated pesticidal polypeptide from strains of Bacillus thuringiensis encoding delta -endotoxins having pesticidal activity against insect pests |
| 09/12/2006 | US7105331 ICE/CED-3 like protease designated FMH-1 |
| 09/12/2006 | US7105330 Immunoglobulin for detection and isolation of preferential glycosidase; tumor diagnosis and antitumor agents |
| 09/12/2006 | US7105323 Residues of glutamic acid and aspartic acid in a channel of apoferritin complex are substituted with small polar amino acid residues, serine, or basic amino acid residues, lysine; preventing a repulsive electrostatic interaction |
| 09/12/2006 | US7105317 Immunogenic compositions comprising vrg-gene products from Bordetella extracts |
| 09/12/2006 | US7105314 Natural insulin B chain lacking the B30 amino acid residue and a natural insulin A chain, a peptide sequence of one Pro not longer than 10 amino acid residues in length; connecting peptide with a cleavage site at its C-terminal |
| 09/12/2006 | US7105305 Human platelet-derived growth factor receptors |
| 09/12/2006 | US7105303 Antibodies to hepatitis C virus asialoglycoproteins |
| 09/12/2006 | US7105291 Detecting sensitivity to kidney disease |
| 09/12/2006 | US7105290 Detect compound which binds to bone morphogenic protein receptors; obtain sample, incubate with binding agent, allow binding, detect complex formation between binding agent and receptors |
| 09/12/2006 | US7105229 Dispersing a matrix of nanostructured liquid phase or a dehydrated variant and a nanostructured liquid crystalline phase or a dehydrated variant in nonlamellar material; cooling or evaporating a volatile solvent |
| 09/12/2006 | US7105182 Periodontal regeneration composition and method of using same |
| 09/12/2006 | US7105181 Microparticles |
| 09/12/2006 | US7105171 Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia |
| 09/12/2006 | US7105169 Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
| 09/12/2006 | US7105168 PlGF results in functional improvement of a skeletal muscle in a mammal after a skeletal muscle ischemic event |
| 09/12/2006 | US7105167 Administering variants of insulin-like growth factor I to treat hyperglycemic disorder, congestive heart failure, urogenital disorders, poor nutrition, or a wasting syndrome |
| 09/12/2006 | US7105166 Soluble CTLA4 mutant molecules and uses thereof |
| 09/12/2006 | US7105165 Mutant human hepatitis B viral strain and uses thereof |
| 09/12/2006 | US7105163 Mite protein |
| 09/12/2006 | US7105162 Peptide or protein from a pathogenic or tumor agent having immunomodulatory activity with an adjuvant capable of increasing the binding of the peptide to the cells of the individual or increasing the entry of the peptide into the cells; strengthening immunomodulatory activity; polyamino acids adjuvants |
| 09/12/2006 | US7105161 Proteinaceous adjuvants |
| 09/12/2006 | US7105160 Antibody-serum protein hybrids |
| 09/12/2006 | US7105158 Methods of administering microencapsulated materials for immune modulated diseases |
| 09/12/2006 | US7105154 Orally administering interferon-tau to intestinal tract to produce measureable increase in patient's blood level of 2*,5*-oligoadenylate synthetase (OAS); autoimmune disease, viral infection and cancer treatment |
| 09/12/2006 | CA2346539C Compositions and methods for enhancing receptor-mediated cellular internalization |
| 09/12/2006 | CA2247179C Use of il-7 for treating auto-immune diseases and insulin-dependent diabetes mellitus in particular |
| 09/12/2006 | CA2236598C Treatment of cardiomyopathy by removal of autoantibodies |
| 09/12/2006 | CA2140929C Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
| 09/08/2006 | WO2006094095A2 Long lasting waterproof sunscreen comprising metal oxide and peptide conditioner |
| 09/08/2006 | WO2006093813A2 Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer |
| 09/08/2006 | WO2006093808A1 Formulations and methods for delivery of growth factor analogs |
| 09/08/2006 | WO2006093337A1 Preventive/therapeutic agent for cancer |
| 09/08/2006 | WO2006093277A1 Soybean transformant having functional peptide therein and use of the same |
| 09/08/2006 | WO2006093222A1 Inhibitor for insulin polymer formation |
| 09/08/2006 | WO2006093211A1 Anti-viral agent |
| 09/08/2006 | WO2006093164A1 Virus infection and proliferation inhibitor containing earthworm-derived component |
| 09/08/2006 | WO2006093143A1 Model for nash or liver tumor, method for production of the model, method for screening of therapeutic agent for nash or liver tumor, method for analysis of mechanism for development of nash or liver tumorm, and agent for prevention or treatment of nash |
| 09/08/2006 | WO2006093071A1 ANTI-IDIOTYPE ANTIBODY HAVING ANTIFUNGAL ACTIVITY ON FUNGUS CARRYING β-GLUCAN SYNTHASE AND UTILIZATION OF THE SAME |
| 09/08/2006 | WO2006093034A1 Mental disorder-related gene and use of the same |
| 09/08/2006 | WO2006093030A1 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |
| 09/08/2006 | WO2006092722A1 Peptidomimetic compounds and preparation of biologically active derivatives |
| 09/08/2006 | WO2006092640A1 Antiproliferative peptides containing the motif phe-trp-leu, pharmaceutical compositions and medical uses thereof |
| 09/08/2006 | WO2006092580A1 Combination therapy |
| 09/08/2006 | WO2006092326A2 Mimetic peptides and the use thereof in the form of 20s, 26s and immunoproteasome inhibitors |
| 09/08/2006 | WO2006092313A1 Lipopeptides having pharmaceutical activity |
| 09/08/2006 | WO2006092046A1 Hiv vaccine composition |
| 09/08/2006 | WO2006081279A3 Control of drug release by transient modification of local microenvironments |
| 09/08/2006 | WO2006067402A3 Agents inibiting the cathelin-like protein cap18/ll-37 |
| 09/08/2006 | WO2006065495A3 Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens |
| 09/08/2006 | WO2006065301A3 Compositions for treatment of ear infections |
| 09/08/2006 | WO2006052723A3 G protein coupled receptor agonists and antagonists and methods of use |
| 09/08/2006 | WO2006050244A3 Treatment of short bowel syndrome patients with colon-in-continuity |
| 09/08/2006 | WO2006044596A3 Multi-domain amphipathic helical peptides and methods of their use |
| 09/08/2006 | WO2006042847A3 Method for the preparation of oxime, thiazolidine, dithiane, dithiolane or hydrazone linked analogues of growth hormone |
| 09/08/2006 | WO2006041488A8 Immortalized hepatocytes |
| 09/08/2006 | WO2006039652A3 Chondroitin sulfate a binding domains |
| 09/08/2006 | WO2006037810A3 Protracted glp-1 compounds |
| 09/08/2006 | WO2006032053A3 Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds |
| 09/08/2006 | WO2006029634A3 Pharmaceutical compositions containing insulin and insulinotropic peptide |
| 09/08/2006 | WO2006023211A3 Antigens targeted by pathogenic ai4 t cells in type 1 diabetes and uses thereof |
| 09/08/2006 | WO2005076744A3 Method for the preparation of peptide-oligonucleotide conjugates |
| 09/08/2006 | WO2005062962A3 Methods and compositions for directing migration of neural progenitor cells |
| 09/08/2006 | WO2005059515A3 Method for treating neurological disorders |
| 09/08/2006 | WO2005051980A8 Depeptidized inhibitors of hepatitis c virus ns3 protease |
| 09/08/2006 | WO2005032456A3 Tricalcium phosphates, their composites, implants incorporating them, and methods for their production |
| 09/08/2006 | WO2005025517A3 Animal model for protease activity and liver damage |
| 09/08/2006 | WO2005017097A3 Quorum sensing and biofilm formation |
| 09/08/2006 | WO2005014849A3 Genes associated with responses to neuropathic pain |
| 09/08/2006 | WO2004089290A3 Novel probiotic compositions and methods of using the same |
| 09/08/2006 | WO2004029071A3 Mage-c2 antigenic peptides and uses thereof |
| 09/08/2006 | WO2003086273A8 Histone conjugates and uses thereof |
| 09/08/2006 | CA2600628A1 Combination of egf/ghrp-6 for neurogeneration of central nervous system following autoimmune damage |
| 09/08/2006 | CA2600453A1 Semi-synthetic glycopeptides with antibiotic activity |
| 09/08/2006 | CA2599876A1 Peptidomimetic compounds and preparation of biologically active derivatives |
| 09/08/2006 | CA2599875A1 Preventive/therapeutic agent for cancer |
| 09/08/2006 | CA2599864A1 Peptide-mimetics and use thereof as inhibitors of the 20s proteasome, 26s proteasome and the immunoproteasome |
| 09/08/2006 | CA2599332A1 Method and composition for repairing heart tissue |
| 09/08/2006 | CA2599297A1 Semi-synthetic desmethyl-vancomycin-based glycopeptides with antibiotic activity |
| 09/08/2006 | CA2599240A1 Fgf growth factor analogs |
| 09/08/2006 | CA2599205A1 Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer |
| 09/08/2006 | CA2599134A1 Formulations and methods for delivery of growth factor analogs |
| 09/08/2006 | CA2599016A1 Compositions and methods for topical application and transdermal delivery of an oligopeptide |
| 09/08/2006 | CA2598833A1 Anti-angiogenic compounds |
| 09/08/2006 | CA2575611A1 Covalent tethering of functional groups to proteins and substrates therefor |
| 09/07/2006 | WO2006069220A9 Modified human growth hormone |
| 09/07/2006 | WO2006033912B1 Treatment of bone disorders with skeletal anabolic drugs |
| 09/07/2006 | US20060200069 Transdermal drug delivery devices having coated microprotrusions |
| 09/07/2006 | US20060199947 Naturally-occurring variants of B7 proteins produced by alternative RNA splicing or alternative termination of full-length amino acid sequence; regulation of immune response in an animal; immunostimulants; anticarcinogenic agents, infections; antiallergens; antiinflammatory agents; veterinary medicine |
| 09/07/2006 | US20060199946 Apoptosis inducing agent and method for inducing apoptosis |
| 09/07/2006 | US20060199843 Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| 09/07/2006 | US20060199840 Chemical derivatives and their application as antitelomerase agent |
| 09/07/2006 | US20060199793 Sterol absorption inhibitor compounds |
| 09/07/2006 | US20060199787 N-(2-acetamidoethyl)phosphonoformamide; inhibiting effect on zinc-containing proteinases, inhibiting cancer cells |
| 09/07/2006 | US20060199782 Gene therapy using a SYN3 and SYN3 homolog delivery enhancing agent with an interferon protein or an interferon gene delivery system; anticarcinogenic agents |